Company profile

Ticker
PVCT
Exchange
CEO
Bruce Horowitz
Employees
Incorporated in
Location
Fiscal year end
Former names
Provectus Pharmaceutical Inc, Provectus Pharmaceuticals Inc, SPM Group Inc, Zamage Digital Imaging Inc
SEC CIK
IRS number
900031917

PVCT stock data

(
)

Calendar

8 Aug 19
25 Aug 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue
Net income -2.18M -1.37M -2.19M -1.61M
Diluted EPS -0.01 0 0 0
Operating income -1.84M -1.8M -1.9M -1.36M
Net change in cash -443.67K 1.72M -180.93K 101.29K
Cash on hand 1.32M 1.77M 50.99K 231.92K
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 0
Net income -8.15M -13.52M -24.43M -24.5M
Diluted EPS -0.02 -0.04 -0.12 -0.13
Operating income -8.05M -13.32M -24.51M -24.65M
Net change in cash -54.52K -1.06M -13.01M -3.21M
Cash on hand 50.99K 105.5K 1.17M 14.18M

Financial data from company earnings reports

Financial report summary

?
Competition
ICH
Management Discussion
  • Research and development costs totaling $4,747,557 for 2018 included payroll of $521,969, consulting and contract labor of $3,053,753, lab supplies and pharmaceutical preparations of $83,134, conferences of $20,976, insurance of $285,853, rent and utilities of $65,989, depreciation and amortization expense of $679,767, and miscellaneous expenses of $36,116.
  • Research and development costs totaling $8,203,926 for 2017 included payroll of $509,615, consulting and contract labor of $6,407,863, conferences of $84,960, lab supplies and pharmaceutical preparations of $147,272, insurance of $310,432, rent and utilities of $56,799, and depreciation and amortization expense of $686,985.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abovementioned, achieve, acidic, activation, activity, Acute, administered, aka, allocated, autophagy, baseline, behalf, biological, blood, blue, breast, bright, burden, cancer, carcinoma, care, central, characterizing, checkpoint, Christian, CI, closure, collateral, colorectal, component, consented, contrast, costly, Dale, de, degradation, deliver, demonstrate, die, disclaimed, disodium, display, distinct, Don, duration, Duve, environment, Ewing, exposure, expression, factor, family, FDA, Food, formulation, GI, Glenn, goal, hematology, hepatocellular, high, higher, highly, human, ideal, identical, immune, imputed, inflamed, inflammasome, inhibitor, injectable, injection, input, insoluble, intracellular, intratumoral, lactone, led, lesional, leukemia, linked, low, Lumenal, lung, lysosomal, manufacturing, mechanism, membrane, mL, model, monotherapy, murine, mutation, negotiated, negotiating, neuroblastoma, neuroendocrine, Nobel, ocular, opportunity, option, Orphan, osteosarcoma, personnel, physicochemical, plasmalemma, play, Pledge, POC, prepayment, Prize, pro, product, protected, quicken, randomized, rapid, rata, red, regulatory, removed, Repayment, represent, resistant, restricted, rhabdomyosarcoma, role, rupture, safety, saline, salt, sarcoma, selectively, showed, shown, skin, SOC, soluble, solution, specifically, staining, strategy, suicide, supplied, Systemic, table, tissue, trap, treated, treatment, trial, trypan, unknown, unmet, utilize, uveal, valuation, vested, vesting, Viral, volatility
Removed: amortization, applicability, auditing, automatically, breach, Carolina, Circuit, clinically, complementary, comply, conference, contract, depreciation, duty, earlier, equal, fiduciary, important, intentional, iv, Knox, lab, Mecklenburg, misrepresentation, negligence, negligent, North, patent, patient, pharmaceutical, primarily, program, radiotherapy, rational, single, stage, targeted, therapeutic, transition, travel, widely